Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0001387131-22-000412
Filing Date
2022-01-18
Accepted
2022-01-18 16:50:45
Documents
2
Group Members
DAVID BONDERMANJAMES G. COULTERJON WINKELRIED

Document Format Files

Seq Description Document Type Size
1 AMENDED SC13D allogene_sc13da-011822.htm SC 13D/A 125859
2 AGREEMENT OF JOINT FILING ex1.htm EX-1 6365
  Complete submission text file 0001387131-22-000412.txt   133810
Mailing Address 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080 (650) 457-2700
Allogene Therapeutics, Inc. (Subject) CIK: 0001737287 (see all company filings)

EIN.: 823562771 | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-90685 | Film No.: 22535730
SIC: 2836 Biological Products, (No Diagnostic Substances)

Mailing Address 301 COMMERCE STREET SUITE 3300 FORT WORTH TX 76102
Business Address 301 COMMERCE STREET SUITE 3300 FORT WORTH TX 76102 (817) 871-4000
TPG GP A, LLC (Filed by) CIK: 0001903793 (see all company filings)

EIN.: 872054646 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A